CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA

临床试验：慢性淋巴细胞白血病

• 批准号: 7718509
• 负责人: MARGARET K-H YU
• 金额: $ 0.53万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718509
• 关键词: Chronic Lymphocytic Leukemia; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; DNA Methylation; Disease; Dysmyelopoietic Syndromes; Funding; Grant; Institution; Malignant Neoplasms; Patients; Research; Research Personnel; Resources; Source; Tumor Suppressor Genes; United States National Institutes of Health; Vidaza; inhibitor/antagonist; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lymphocytic leukemia is rarely curative disease. Novel treatments are needed. Like many other malignancies, tumor suppressor genes may be silenced by DNA methylation in chronic lymphocytic leukemia. Vidaza, a DNA methylation inhibitor, is already approved for treatment of patients with myelodysplastic syndrome. This study proposes to study if Vidaza is an effective DNA methylation inhibitor in patients with chronic lymphocytic leukemia.

这个子项目是众多研究子项目之一